Jacquelyn L. Sumer

CIK: 0001844824

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (62.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CGEM

Cullinan Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

CGEM
Cullinan Therapeutics, Inc.
Jun 30, 2026
Award(A)
Direct
2.5K shares at avg. $8.60$21K
CGEM
Cullinan Therapeutics, Inc.
Feb 24, 2026
Sale(S)
Direct
3.6K shares at avg. $14.47$52K
CGEM
Cullinan Therapeutics, Inc.
Feb 20, 2026
Sale(S)
Direct
3.7K shares at avg. $13.62$51K
CGEM
Cullinan Therapeutics, Inc.
Feb 18, 2026
Award(A)
Stock Option (Right to Buy)
Direct
230K shares-
CGEM
Cullinan Therapeutics, Inc.
Dec 18, 2025
Sale(S)
Direct
3.5K shares at avg. $9.67$34K
CGEM
Cullinan Therapeutics, Inc.
Feb 25, 2025
Sale(S)
Direct
3.8K shares at avg. $8.53$32K
CGEM
Cullinan Therapeutics, Inc.
Feb 19, 2025
Award(A)
Direct
50K shares-
CGEM
Cullinan Therapeutics, Inc.
Dec 18, 2024
Sale(S)
Direct
3.5K shares at avg. $11.41$40K

		Type	Shares	Price		Ownership
Jun 30, 2026	CGEM Cullinan Therapeutics, Inc.	Award(A)	2,470	$8.60	$21,242	Direct
Feb 24, 2026	CGEM Cullinan Therapeutics, Inc.	Sale(S)	3,601	$14.47	$52,106	Direct
Feb 20, 2026	CGEM Cullinan Therapeutics, Inc.	Sale(S)	3,742	$13.62	$50,966	Direct
Feb 18, 2026	CGEM Cullinan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	230,000	-	-	Direct
Dec 18, 2025	CGEM Cullinan Therapeutics, Inc.	Sale(S)	3,480	$9.67	$33,652	Direct
Feb 25, 2025	CGEM Cullinan Therapeutics, Inc.	Sale(S)	3,756	$8.53	$32,039	Direct
Feb 19, 2025	CGEM Cullinan Therapeutics, Inc.	Award(A)	50,000	-	-	Direct
Dec 18, 2024	CGEM Cullinan Therapeutics, Inc.	Sale(S)	3,482	$11.41	$39,730	Direct

1-8 of 8 transactions

About SUMER JACQUELYN L

SUMER JACQUELYN L (SEC CIK 0001844824) files insider reports with the SEC as Chief Legal Officer of Cullinan Therapeutics, Inc. (CGEM).

Signal8 holds 8 ownership filings by SUMER JACQUELYN L, all Form 4s, filed between Dec 20, 2024 and Jul 2, 2026. Those filings report 8 transactions, from Dec 18, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SUMER JACQUELYN L's filings is in CAMBRIDGE, MA.

Recent filings by SUMER JACQUELYN L

Jun 30, 2026: Grant or award of CGEM shares (Form 4, code A).
Feb 24, 2026: Open-market sale of CGEM shares (Form 4, code S).
Feb 20, 2026: Open-market sale of CGEM shares (Form 4, code S).
Feb 18, 2026: Grant or award of CGEM derivative securities (Form 4, code A).
Dec 18, 2025: Open-market sale of CGEM shares (Form 4, code S).

Other insiders filing for Cullinan Therapeutics, Inc. (CGEM)

Michaelson Jennifer, Chief Scientific Officer
Fenton Mary Kay, Chief Financial Officer
Rosenberg Anthony, Director
Meek David D., Director
Webster Stephen W, Director
Allen Andrew R, Director

How to read Form 4 transaction codes